Human Trop-2 Monoclonal Antibody
Product Sizes
1 mg
£355.00
YR0018-1MG
5 mg
£885.00
YR0018-5MG
20 mg
£1721.00
YR0018-20MG
About this Product
- SKU:
- YR0018
- Additional Names:
- EGP-1|EGP1|GA733-1|GA7331|GP50|M1S1|TACSTD2|TROP2
- Application:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Clonality:
- Monoclonal
- Extra Details:
- Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2.Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Human Trop-2
- Isotype:
- IgG1, kappa
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- ABclonal Technology
- Type:
- Antibody: Biosimilar Antibody
- Manufacturer's Data Sheet:YR0018
